We’re pleased to share commercial growth highlights, including preliminary 4Q and full year 2024 revenue, as well as our strategic priorities. CEO Cedric Francois will be discussing these updates today at #JPM25 at 9:45 a.m. PT. Read more: bit.ly/40vJWLW $APLS

We are excited to announce that our #GeographicAtrophy (GA) treatment is now approved in Australia! Read more in our press release: bit.ly/4aCm50k This is a significant milestone for GA patients. #WeAreApellis

Tomorrow is #RareDiseaseDay! Join us and #ShowYourStripes to raise awareness and support for the rare disease community. Check out the resources from the National Organization for Rare Disorders (NORD) to learn more: bit.ly/3EU2mhd #WeAreApellis #RDD2025

Today, we are proud to share our Q4 2024 financial results and highlights. $APLS bit.ly/4khL11L

Special thanks to our wonderful contributors for providing their impactful perspectives on glomerular diseases, particularly #C3G and #ICMPGN and to Apellis Pharma, Inc. for sponsoring this Digital Spotlight. You can read all articles here: rarerevolutionmagazine.com/digital_spotli…

Attending the Pediatric Academic Societies? Stop by booth #1107 to learn more about our work in C3G and primary IC-MPGN. #PAS #WeAreApellis

We’re excited to share 8 abstracts, including 2 oral presentations and 6 posters, at this year’s Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Salt Lake City. #ARVO2025 #WeAreApellis ARVO

Today, we shared our Q1 2025 financial results and highlights. Learn more: bit.ly/4iO4Pb6 $APLS

Calling all U.S. Retina Fellows! Apellis is accepting proposals for a research grant supporting clinical innovation in #GeographicAtrophy (GA). Learn more: bit.ly/44GaZXw 🎯 Who can apply: US Retina Fellows 📌 Focus: Advancing GA research 📅 Apply by: 8/20/25

Attending the ERA - European Renal Association meeting this week? We're looking forward to sharing more about our research in C3G and IC-MPGN. #WeAreApellis #ERA2025

We’re excited to share new one-year data from the Phase 3 VALIANT study in C3G and primary IC-MPGN, which were presented as part of a late-breaking session at the ERA - European Renal Association Congress. Learn more: bit.ly/3FAmlSJ #ERA2025

We're excited to announce Apellis will receive up to $300M from a royalty agreement with our partner Sobi for ex-U.S. royalties of our rare disease treatment. This deal reflects our potential to transform #rarediseases, including C3G and primary IC-MPGN. bit.ly/3ZZVDdf

We’re proud to support RARE Revolution Magazine’s upcoming webinar on patient and caregiver experiences with C3G and primary IC-MPGN. Explore below.

We look forward to sharing five data presentations on #GeographicAtrophy (GA) at the ASRS Annual Scientific Meeting. Learn more: bit.ly/44vmkJr See you there! #ASRS2025 #WeAreApellis

#Breaking news: We’re thrilled to announce that the U.S. FDA approved our treatment for C3G and primary IC-MPGN, two rare and severe kidney diseases. bit.ly/4mgFOHC This is the first approved treatment for C3G and primary IC-MPGN for patients 12 and older. #RareDisease

#TeamApellis is live at the ASRS Annual Scientific Meeting! Visit us at booth 129 and check out our five presentations on #GeographicAtrophy: bit.ly/44vmkJr #ASRS2025 #WeAreApellis

Today, we shared our Q2 2025 financial results and highlights. Learn more: bit.ly/40IwcgH $APLS

Attending the World Transplant Congress (WTC) this week? Visit us at booth #715 to learn more about our work in #RareDisease, including our recently approved treatment for C3G and primary IC-MPGN. #WTC2025 #WeAreApellis

For the first time, patients 12 and older have an approved treatment option for C3G and primary IC-MPGN. Read about this exciting update: bit.ly/4mgFOHC These rare kidney diseases often lead to kidney failure, requiring lifelong dialysis or a kidney transplant.

Applications are still open! Apply by August 20, 2025 at bit.ly/44GaZXw. US Retina Fellows are invited to submit proposals for a research grant supporting clinical innovation in #GeographicAtrophy (GA). #WeAreApellis